Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
ResMed Inc. is a global medical technology company focused on developing, manufacturing, and distributing products and cloud-based solutions for the diagnosis, treatment, and management of sleep-disordered breathing, chronic obstructive pulmonary disease (COPD), and other chronic respiratory conditions. The company primarily operates within the medical devices, digital health, and healthcare software industries, with a strong emphasis on connected care and data-driven patient management.
ResMed’s core revenue drivers include positive airway pressure (PAP) devices, masks, and accessories, as well as subscription-based and software-as-a-service (SaaS) offerings supporting healthcare providers and home medical equipment (HME) companies. The company serves sleep clinics, hospitals, physicians, HMEs, and patients directly in both acute and home-care settings. Founded in 1989, ResMed evolved from a device-centric manufacturer into a digitally integrated healthcare company, leveraging cloud connectivity and analytics to improve clinical outcomes and operational efficiency.
Business Operations
ResMed operates through two primary business segments: Sleep and Respiratory Care and Software as a Service. The Sleep and Respiratory Care segment generates the majority of revenue through sales of PAP devices, ventilators, masks, and related accessories used to treat sleep apnea and respiratory insufficiency. These products are sold through a combination of direct sales and third-party distributors across domestic and international markets.
The Software as a Service segment includes cloud-based platforms that support out-of-hospital care, patient monitoring, and healthcare business operations. Key assets include proprietary digital platforms that enable remote patient management, data analytics, and workflow optimization. ResMed controls a vertically integrated ecosystem combining hardware, software, and data services, with operations supported by manufacturing facilities, R&D centers, and sales organizations worldwide.
Strategic Position & Investments
ResMed’s strategic direction centers on expanding its leadership in connected medical devices while scaling its recurring-revenue digital health platforms. Growth initiatives include increased investment in cloud-based healthcare software, data interoperability, and automation solutions for providers managing chronic disease populations. The company has pursued targeted acquisitions to strengthen its software portfolio and deepen its presence in out-of-hospital care.
Notable subsidiaries include ResMed SAS, ResMed Corp., and digital health platforms such as Brightree, MatrixCare, and myAir, which collectively support home health, post-acute care, and patient engagement. ResMed is actively involved in emerging areas such as remote patient monitoring, AI-enabled data analytics, and value-based care infrastructure, aligning its technology development with broader healthcare system digitization trends.
Geographic Footprint
ResMed is headquartered in San Diego, California, and operates in more than 140 countries worldwide. The company has significant market presence across North America, Europe, Asia-Pacific, and Latin America, with particularly strong positions in the United States, Australia, Germany, France, and Japan.
Manufacturing, research, and development activities are distributed globally, including facilities in Australia, Singapore, France, and Malaysia. International markets account for a substantial portion of ResMed’s revenue, and the company maintains regional offices and subsidiaries to support localized regulatory, clinical, and commercial requirements.
Leadership & Governance
ResMed’s leadership emphasizes innovation, patient-centric design, and long-term value creation through digital transformation in healthcare. The company operates under a governance framework aligned with U.S. public company standards, with oversight provided by an independent board of directors and executive leadership team.
Key executives include:
- Michael J. Farrell – President and Chief Executive Officer
- Brett Sandercock – Chief Financial Officer
- Mick Farrell – Chairman of the Board
- Justin Leong – Chief Product Officer
- Rob Douglas – President, SaaS Business
Leadership philosophy focuses on improving patient outcomes, enabling healthcare providers, and scaling sustainable, technology-driven solutions for chronic disease management.